Accordingly, it has been shown that BACE1 inhibition efficiently lowers Aβ levels in the central nervous system of healthy subjects and AD patients (Forman et al., 2012; Neumann et al., 2015; Thakker et al., 2015; Kennedy et al., 2016). This evidence concerns the gene BACE1 and Alzheimer disease.